Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: In vitro and in vivo evaluation

Cancer Letters

Volumn 315, Issue 1, 2012, Pages 69-77

  Sun, Nian feng ^a,b   Meng, Qing yi ^a   Tian, Ai ling ^a   Hu, San yuan ^b   Wang, Rui hua ^a   Liu, Zhao xuan ^a   Xu, Li ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Colon cancer; Gene therapy; Nanoliposomes

Indexed keywords

GREEN FLUORESCENT PROTEIN; LIPOSOME; NANOLIPOSOME; RED FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR 3 LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; DIGESTION; DRUG EFFICACY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; RESTRICTION MAPPING; TREATMENT RESPONSE;

ANIMALS; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIPOSOMES; LUMINESCENT PROTEINS; MALE; MEMBRANE PROTEINS; MICE; NANOPARTICLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 81955167365     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.010     Document Type: Article

References (24)

1. Yonemura Y., Ku H., Lyman S.D., Ogawa M., Kato T., Miyazaki H. In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between Flt3/Flk2 ligand and kit ligand. Blood 2002, 99:1915-1918.
2. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
3. Haylock D.N., Horsfall M.J., Dowse T.L., Ramshaw H.S., Niutta S., Protopsaltis S., Peng L., Burrell C., Rappold I., Buhring H.-J., Simmons P.J. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of flt3 ligand. Blood 1997, 90:2260-2262.
4. Maliszewski C. Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Pathol. Biol. 2001, 49:481-483.
5. Park Soo-Jung, Kim Mi-Ju, Kim Hak-Bong Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp. Cell Res. 2009, 15:1809-1818.
6. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy, cytokine. Growth Factor Rev. 2003, 14:337-348.
7. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003, 10:66-75.
8. Holoch P.A., Griffith T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol. 2009, 625:63-72.
9. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
10. Lindgren M., Rosenthal-Aizman K., Saar K. Overcoming metho-trexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem. Pharmacol. 2006, 71:416-425.
11. Suzuki H., Kuzumaki S., Nakagawa K. Suppressive effect of modified mominant negative RAS mutant on human cancer by gene transfer with non-viral vector. Cancer Biol. Ther. 2006, 5:1487-1491.
12. 3. Biochem. Biophys. Res. Commun. 2004, 11:899-903.
13. Kim E.M., Sivanandham M. Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model. J. Surg. Res. 2002, 108:148-156.
14. Maliszewski C. Dendritic cells in models of tumor immunity: Role of Flt3 ligand. Pathol. Biol. (Paris). 2001, 49:481-483.
15. Ganten Tom M., Sykora Jaromir Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J. Mol. Med. 2009, 87:995-1007.
16. Yildiz Ramazan, Benekli Mustafa, Buyukberber Suleyman The eVect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J. Cancer Res. Clin. Oncol. 2010, 136:1471-1476.
17. Daniel Borja-Cacho, Yumi Yokoyama, Rohit K. TRAIL and Triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. J. Gastrointest. Surg. 2010, 14:252-260.
18. Wang Wen-Bo, Zhou Yu-Lin, Heng De-Feng Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Breast. Cancer Res. Treat 2008, 110:283-295.
19. Newsom-Davis Thomas, Prieske Silvia, Walczak Henning Is TRAIL the holy grail of cancer therapy?. Apoptosis 2009, 14:607-623.
20. Yamanaka R., Honma J., Tsuchiya N. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J. Neurooncol. 2005, 72:107-113.
21. Daniel Volker, Naujokat Cord, Sadeghi Mahmoud Association of IL-12+ DC with high CD3+CD4-DR+lymphocyte counts in long-term HIV-infected Hemophilia patients with clinically stable disease. J. Clin. Immunol. 2008, 28:58-72.
22. Sheng K.C., Pietersz G.A., Wright M.D. Dendritic cells: activation and maturation-applications for cancer immunotherapy. Curr. Med. Chem. 2005, 12:1783-1800.
23. Delluc Stéphanie, Hachem Patricia, Rusakiewicz Sylvie Dramatic eYcacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol. Immunother. 2009, 58:1669-1677.
24. Del P.A., Delgado D., Solinis M.A., Gascon A.R., Pedraz J.L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 2007, 339:261-268.